Sign in
Create a Profile
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Diseases and Conditions Researched
Schizoaffective Disorder; Schizophrenia
What is the purpose of this trial?
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
Participation Guidelines
Gender: Both
Click here for detailed participation information for this trial.
| Sponsors: | Stanley Medical Research Institute; Yale University |
|---|---|
| Dates: | December 29, 2007 |
| Last Updated: | August 10, 2010 |
| Study HIC#: | 0710003164 |
| Clinicaltrials.gov ID: | NCT00588731 |
How will my information be used?
For more information about this trial, contact:
Ashley M Schnakenberg, B.S.
203-932-5711
Ext. 4485
ashley.schnakenberg@yale.edu
Principal Investigator
Ranganathan, Mohini
Psychiatry
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
